Huons Co., Ltd. (KOSDAQ:243070)

South Korea · Delayed Price · Currency is KRW

25,550

+100 (0.39%)

Jul 21, 2026, 3:30 PM KST

-15.40% (1Y)

Market Cap	297.70B -15.7%
Revenue (ttm)	616.80B +4.8%
Net Income	30.69B -3.7%
EPS	2,611.50 -0.4%
Shares Out	11.65M
PE Ratio	9.78
Forward PE	n/a
Dividend	920.00 (3.61%)
Ex-Dividend Date	May 26, 2026

Volume	16,189
Open	24,150
Previous Close	25,450
Day's Range	24,150 - 26,100
52-Week Range	24,000 - 41,500
Beta	0.22
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 11, 2026

About Huons

Huons Co., Ltd. provides medical solutions for human health in Korea and internationally. The company offers oral solid form drugs, including circulatory system, metabolic, antipyretic, analgesic, anti-inflammatory, musculoskeletal system, digestive system, antihistamine, respiratory system, anti-coagulant, antiviral, central nervous system, antibiotic, well-being, urogenital system, and other chemotherapeutic products; and injection products, such as anesthetic, antipyretic, analgesic, anti-inflammatory, skeletal muscle relaxant, antispasmodic... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1965

Employees 912

Stock Exchange KOSDAQ

Ticker Symbol 243070

Full Company Profile

Financial Performance

In 2025, Huons's revenue was 620.77 billion, an increase of 5.17% compared to the previous year's 590.23 billion. Earnings were 42.66 billion, an increase of 44.84%.

Financial Statements